CD82 and prostate cancer: Downregulation of TM4SF1 expression on the cell surface led to significant increases in CD63 and CD82, which were negatively related to the motility of diverse cell types, overexpression of CD82 in prostate cancer cells resulted in alterations in the FAK-Lyn-p130CAS-CrkII signaling pathway, which correlated with decreased cell motility (Bernard, 2018).